- Organizations: VeonGen Therapeutics
Pipeline
VeonGen on track for phase 3 Stargardt trial after FDA meeting
Phase 1/2 trial data demonstrate favorable safety profile and BCVA improvements; company has met with the FDA to plan the phase 3 program.Pipeline
FDA grants RMAT designation to VeonGen's Stargardt therapy
Status marks third designation for the VG801, intended to treat patients with biallelic ABCA4 mutations linked to Stargardt disease and related retinal dystrophiesPipeline